MDM2 PROTAC | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,725 results for “MDM2 PROTAC”

Trials

View all 1270 →

First Human Trial of Targeting MDM2/MDMX PET Imaging

3 participants · First posted Jun 5, 2024

Effects of Systematic Proprioceptive-tactile Stimulation With Use of the Protac MyFit®

240 participants · First posted Nov 22, 2019

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

21 participants · First posted Aug 31, 2018

Drugs

View all 252 →

MDM2-PROTAC(Hansohbio)

PROTAC MDM2 Degrader-4(Shaoxing University)

PROTAC MDM2 Degrader-3(Shaoxing University)

Organizations

View all 11 →

Arvinas

United States

Rein Therapeutics

Hinova Pharmaceuticals Inc.

News

View all 192 →

Novel Anti-MDM2 PROTAC Shows Promise for p53-Mutated Cancer Treatment

PROTACs: A Promising New Class of Targeted Protein Degraders Set to Revolutionize Disease Treatment

Arvinas CEO John Houston Announces Retirement Following PROTAC Breakthrough Success

Page 1 of 173